Advanced Antibody Explorers
“We bring
science to life.”
AAX Biotech is committed to advancing next-generation therapies for a range of diseases. With a focus on antibody-based medicines, our proprietary technologies aim to solve key challenges in drug development. Our vision is to establish AAX as a leading, highly competitive partner serving the bio-pharma industry worldwide.
About us
We are a research-driven company focused on enabling and accelerating the development of highly effective antibody-based medicines. By offering innovative solutions to well-recognized challenges in the rapidly expanding biotherapeutics market, we aim to accelerate drug development and improve therapeutic outcomes.
Supported by
“Their Seqitope® technology has provided a level of insight into the interaction between our drug candidates and their target that was previously unattainable using conventional epitope mapping techniques.”
— Christer Nordstedt, Chief Executive Officer, Oblique Therapeutics
News
.
News .
News
